CAS 475108-18-0: Tivozanib
Description:Tivozanib, with the CAS number 475108-18-0, is a small molecule tyrosine kinase inhibitor primarily used in the treatment of renal cell carcinoma. It selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), which play a crucial role in angiogenesis, the process by which new blood vessels form from pre-existing ones. This inhibition disrupts tumor blood supply, thereby limiting tumor growth and metastasis. Tivozanib is characterized by its high potency and selectivity, which contribute to its therapeutic efficacy while potentially minimizing off-target effects. The compound is typically administered orally and has a favorable pharmacokinetic profile, including a long half-life, allowing for once-daily dosing. Common side effects may include hypertension, fatigue, and gastrointestinal disturbances. As an investigational drug, Tivozanib has been evaluated in various clinical trials, demonstrating promise in improving outcomes for patients with advanced renal cell carcinoma. Its development reflects ongoing efforts to enhance targeted cancer therapies and improve patient quality of life.
Formula:C22H19ClN4O5
InChI:InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
InChI key:InChIKey=SPMVMDHWKHCIDT-UHFFFAOYSA-N
SMILES:O=C(NC1=NOC(=C1)C)NC2=CC=C(OC=3C=CN=C4C=C(OC)C(OC)=CC43)C=C2Cl
- Synonyms:
- 1-[2-Chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea
- Av-951
- Fotivda
- Kil 8951
- Krn 951
- N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N′-(5-methyl-3-isoxazolyl)urea
- Tivozanib
- Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N′-(5-methyl-3-isoxazolyl)-
- N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N′-(5-methyl-3-isoxazolyl)urea
- AV951(Tivozanib)
- See more synonyms
